

O I P Express Mail No.: EV 869897377 US
Date of Deposit: July 11, 2008

Page 1 of 1
Attorney Docket No.: 27331-501CIP2A

JUL 11 2008

Patent & Trademark Office
Modified Form 1449/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Application Number	10/770,639
Filing Date	February 2, 2004
First Named Inventor	Sanchez-Madrid
Group Art Unit	1644
Examiner Name	Zachary S. Skelding
Attorney Docket Number	27331-501CIP2A

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C45	Hamann et al., "AICL: a new activation-induced antigen encoded by the human NK gene complex", <i>Immunogenetics</i> , 45:295-300 (1997)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4377800v.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./



Express Mail No.: EV 869897377 US
Date of Deposit: July 11, 2008

Page 1 of 1
Attorney Docket No.: 27331-501CIP2A

Modified Form 1449/PTO		Application Number	10/770,639
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	February 2, 2004
		First Named Inventor	Sanchez-Madrid
		Group Art Unit	1644
		Examiner Name	Zachary S. Skelding
		Attorney Docket Number	27331-501CIP2A

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.	
	C45	Hamann et al., "AICL: a new activation-induced antigen encoded by the human NK gene complex", <i>Immunogenetics</i> , 45:295-300 (1997)	

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Zachary Skelding/	Date Considered	07/16/2009
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ACTIVE 4377800v.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./